Vir Biotechnology, Inc.VIREarnings & Financial Report
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
Revenue
$2.4M
Gross Profit
$2.3M
Operating Profit
$-231.3M
Net Profit
$-213.7M
Gross Margin
97.9%
Operating Margin
-9718.7%
Net Margin
-8979.7%
YoY Growth
-9.8%
EPS
$-1.56
Vir Biotechnology, Inc. Q3 FY2024 Financial Summary
Vir Biotechnology, Inc. reported revenue of $2.4M (down 9.8% YoY) for Q3 FY2024, with a net profit of $-213.7M (down 30.8% YoY) (-8979.7% margin). Cost of goods sold was $50.0K, operating expenses totaled $233.6M.
Key Financial Metrics
| Total Revenue | $2.4M |
|---|---|
| Net Profit | $-213.7M |
| Gross Margin | 97.9% |
| Operating Margin | -9718.7% |
| Report Period | Q3 FY2024 |
Vir Biotechnology, Inc. Annual Revenue by Year
Vir Biotechnology, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $74.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $74.2M |
| 2023 | $86.2M |
| 2022 | $1.6B |
Vir Biotechnology, Inc. Quarterly Revenue & Net Profit History
Vir Biotechnology, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $240.0K | -89.9% | $-163.1M | -67975.4% |
| Q2 FY2025 | $1.2M | -60.5% | $-111.0M | -9139.9% |
| Q1 FY2025 | $3.0M | -94.6% | $-121.0M | -3989.6% |
| Q4 FY2024 | $12.4M | -26.3% | N/A | N/A |
| Q3 FY2024 | $2.4M | -9.8% | $-213.7M | -8979.7% |
| Q2 FY2024 | $3.1M | -19.0% | $-138.4M | -4500.1% |
| Q1 FY2024 | $56.4M | -10.5% | $-65.3M | -115.8% |
| Q4 FY2023 | $16.8M | -66.0% | N/A | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.8M | $56.4M | $3.1M | $2.4M | $12.4M | $3.0M | $1.2M | $240000 |
| YoY Growth | -66.0% | -10.5% | -19.0% | -9.8% | -26.3% | -94.6% | -60.5% | -89.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.92B | $1.79B | $1.67B | $1.50B | $1.40B | $1.31B | $1.19B | $1.02B |
| Liabilities | $328.8M | $246.6M | $235.9M | $257.6M | $248.4M | $263.9M | $245.1M | $223.4M |
| Equity | $1.59B | $1.55B | $1.43B | $1.24B | $1.15B | $1.04B | $947.5M | $796.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-778.8M | $-109.4M | $-77.8M | $-171.5M | $-446.4M | $-78.1M | $-120.2M | $-167.6M |